Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
With
Pfizer
Age
0–18
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Functioning central venous catheter in the upper or lower venous system
Cohort A: Asymptomatic patients having placement of a new central venous catheter in the last 40±20 days
Cohort B: Subjects who have experienced symptoms for a CVC-related DVT with a CVC in place or subjects who have been incidentally identified by radiographic imaging (imaging modalities to diagnose an incidental CVC-related DVT may include, but is not exclusive of Echocardiogram, CT scan, MRI, or Ultrasound) performed for other clinical reasons, as having a CVC-related DVT in the veins where the current catheter is placed
Males and females from full-term newborns to \< 18 years
You may not be if
For Cohort A subjects only, present therapeutic dosing of a systematic anticoagulant, systemic thromboprophylaxis or antiplatelet therapy. Local thromboprophylaxis \[flushes, low dose infusions of heparin of up to 5 u/kg/hr or locks with heparin, urokinase, t-plasminogen activator\] according to standard-of-care at the respective center will be allowed
Patients unable to undergo contrast enhanced magnetic resonance imaging
